



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/626,459	07/22/2003	Shuichi Mizuno	3831.03	2554	
7	7590 03/29/2006	EXAMINER			
HANA VERI		NAFF, DAVID M			
PETERS, VER	RNY, JONES & SCHM	ART UNIT	PAPER NUMBER		
425 SHERMA	· · · · · · · · · · · · · · · · · · ·	1651			
PALO ALTO, CA 94306			DATE MAILED: 03/29/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		A		Annlicont(s)				
•		Application	on No.	Applicant(s)				
Office Action Summary		10/626,4	59 	MIZUNO ET AL.				
		Examine	,	Art Unit	<u>-</u> _			
		David M. I		1651				
Period fo	The MAILING DATE of this communicat or Reply	tion appears on the	cover sheet with the	correspondence ad	dress			
WHIC - Exte after - If NC - Failu Any	IORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL ensions of time may be available under the provisions of 37 or SIX (6) MONTHS from the mailing date of this communical period for reply is specified above, the maximum statutoure to reply within the set or extended period for reply will, reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF TH 7 CFR 1.136(a). In no evaction. Try period will apply and we by statute, cause the app	HIS COMMUNICATIO ent, however, may a reply be ti ill expire SIX (6) MONTHS fror dication to become ABANDON	ON. imely filed in the mailing date of this co ED (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed o	on <u>22 July 2003</u> .						
·	•	☐ This action is n	on-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merit								
	closed in accordance with the practice	under <i>Ex parte Qเ</i>	iayle, 1935 C.D. 11, 4	153 O.G. 213.				
Disposit	ion of Claims							
4)🖂	4)⊠ Claim(s) <u>1-21</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)[Claim(s) is/are allowed.							
6)⊠	S)⊠ Claim(s) <u>1-21</u> is/are rejected.							
	Claim(s) is/are objected to.							
8)[]	Claim(s) are subject to restriction	n and/or election r	equirement.					
Applicat	ion Papers			•				
9)[The specification is objected to by the E	xaminer.						
10)[The drawing(s) filed on is/are: a)	accepted or b)	objected to by the	Examiner.				
	Applicant may not request that any objection	n to the drawing(s) t	e held in abeyance. Se	ee 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the	e correction is requir	ed if the drawing(s) is of	bjected to. See 37 CF	R 1.121(d).			
11)	The oath or declaration is objected to by	the Examiner. No	ote the attached Office	e Action or form PT	O-152.			
Priority (under 35 U.S.C. § 119							
· ·	Acknowledgment is made of a claim for All b) Some * c) None of:	foreign priority un	der 35 U.S.C. § 119(a	a)-(d) or (f).				
	1. Certified copies of the priority doc	cuments have bee	n received.					
	2. Certified copies of the priority doc		• •					
	3. Copies of the certified cop	•		ed in this National	Stage			
	application from the International	•	• • • •					
- (See the attached detailed Office action for	or a list of the certi	fied copies not receiv	red.				
Attachmer	• •							
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-	-948)	4) Interview Summar Paper No(s)/Mail D					
3) 🔀 Infor	mation Disclosure Statement(s) (PTO-1449 or PTO		5) Notice of Informal 6) Other:)-152)			

Art Unit: 1651

10

15

20

DETAILED ACTION

Claims examined on the merits are 1-21, which are all claims in the application.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-21 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 1 and where recited in other claims, "in situ formation of a superficial cartilage layer", "superficial cartilage", "neocartilage" and "neo-cartilage construct" are uncertain as to meaning and scope. It is uncertain how "in situ formation" defines the method in addition to the process steps recited. What is the difference in superficial cartilage and neo-cartilage from other cartilage, and how does one know when the cartilage exists as compared to other cartilage?

Dependent claims 5-21 are unclear how they further limit the steps of claim 1. It is unclear as to what steps these claims require being added to claim 1, and how these added steps are combined with the steps of claim 1.

Art Unit: 1651

5

10

15

20

25

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith et al (6,528,052 B1).

The claims are drawn to a method of in situ formation of cartilage layer over an articular cartilage lesion by preparing a cartilage construct from isolated and expanded chondrocytes, implanting the construct, and depositing a sealant over the construct.

Smith et al disclose formation of cartilage *in vitro* from chondrocytes and implanting the cartilage (col 16, lines 40-55).

Art Unit: 1651

10

15

20

25

30

It would have been obvious to seal with a sealant after implanting to prevent contamination of the site of implantation. The cartilage produced before implanting is inherently a construct. A hydrostatic pressure as in claim 12 is disclosed by Smith et al. Embedding chondrocytes in a matrix as in claim 3 would have been obvious since using a matrix as claimed is known in the prior art.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-21 are rejected on the ground of nonstatutory

35 obviousness-type double patenting as being unpatentable over claims 1
16 of U.S. Patent No. 6,949,252 B2. Although the conflicting claims

are not identical, they are not patentably distinct from each other

Art Unit: 1651

5

10

15

because the presently claimed method of forming cartilage would have been obvious from the method of claimed by the patent of preparing an implantable tissue construct for treatment of a cartilage lesion.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David M. Naii Drimary Examiner
Art Unit 1651

20